Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Hepatitis B Treatment Market size was valued at USD 92.61 billion in 2024 and is expected to reach USD 162.09 billion by 2037, expanding at around 4.4% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of hepatitis B treatment is evaluated at USD 96.07 billion.
The growth of the hepatitis B treatment market can be attributed primarily to the growing number of individuals who are infected by the hepatitis B virus, along with the need amongst the individuals to cure the viral infection.
Hepatitis is referred to as an inflammatory condition of the liver and is commonly caused by a hepatitis virus. The most common hepatotropic viruses that cause hepatitis are hepatitis A, B, C, D, and E. Hepatitis B is caused by Hepatitis B virus (HBV) which belongs to the viral family Hepadnaviridae. Viral hepatitis B infections are diagnosed by the use of virus testing diagnostic kits, whereas for non-viral infections, blood tests, liver ultrasound or liver biopsy tests are performed. Recently, with the advancements in medical sciences, rapid testing kits are also being used widely by medical practitioners for the detection of the disease. The treatment of hepatitis B is done by the use of the hepatitis B vaccine or through anti-viral drugs. Though, several players are still in search of developing a new cure for hepatitis B, and few of them are in the development of new drugs and medicines for hepatitis B, as the treatment developed for hepatitis B doesn’t totally eradicate the virus from the human body. Hepatitis B is transmitted commonly through direct contact with infected blood, especially during unsterile healthcare practices, or while giving birth to the newborn by the mother, who is a hepatitis B carrier. Hepatitis B is also transmitted through unprotected sexual intercourse or contact with bodily fluids. Hepatitis B infection in human beings can be either acute or chronic. The United States Food and Drug Administration (FDA) has approved eight different treatment options for the treatment of chronic hepatitis B. These include treatment with tenofovir alafenamide, adefovir, entecavir, pegylated interferon, tenofovir disoproxil, telbivudine, alpha-interferon, and lamivudine.
